CPT 0040U: MRDx BCR–ABL mRNA Test for CML Monitoring
CPT code 0040U is a Proprietary Laboratory Analyses (PLA) code for the MRDx® BCR–ABL assay from MolecularMD. The assay quantifies BCR–ABL mRNA transcripts (e13a2/b2a2 or e14a2/b3a2) with an ABL endogenous control to monitor response in chronic myelogenous leukemia. As a PLA code, 0040U uniquely identifies a single manufacturer’s test and supports clinical monitoring decisions for CML patients receiving targeted therapy.
Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage landscapes and benchmarking where available, with an emphasis on clinical utility, coding specificity, and implications for laboratory billing workflows.
Readers will learn the clinical context for molecular BCR–ABL monitoring, what the PLA designation means for coding and billing, and where to find payer policy details. The report provides benchmarks and policy summaries when available and notes areas where data are not provided in the input. The content is intended for laboratory billing managers, clinicians who oversee CML monitoring, and policy analysts tracking proprietary diagnostic codes.
Customize your policy alerts
Sign up for cpt 0040U policy alerts
Get alerted when payer policies referencing 0040U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0040U is a Proprietary Laboratory Analyses (PLA) code that describes a single proprietary molecular diagnostic assay: the MRDx® BCR–ABL test from MolecularMD. The test measures BCR–ABL mRNA transcripts (e13a2/b2a2 or e14a2/b3a2) and the ABL endogenous control mRNA to monitor patients with chronic myelogenous leukemia (CML).
Service type: Proprietary molecular diagnostic laboratory test (PLA)
Typical site of service: Clinical reference laboratory